Apr 2021 $27 M Private placement after listing $10 to $50 million 47
Immunome Inc.: Private sale, Apr 2021 × Investors in this round 47 investors had bought by the notice of May 11, 2021: 47 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $27 M of $27 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $410,000
Finders' fees none
Paid to its own people $1,300,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Corleen J Roche · Executive Officer Dennis H Giesing · Executive Officer Michael J Morin · Executive Officer Purnanand Sarma · Executive Officer, Director Sandra G Stoneman · Executive Officer John J LaMattina · Director Michael D Widlitz · Director Michael J Lefenfeld · Director Michael J Rapp · Director Philip J Wagenheim · Director Richard J Baron · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New York Sold in all US states Signed by Purnanand D. Sarma, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2021. Read the notice at the SEC .
equity, options SEC Jun 2020 $11 M No. 6 $10 to $50 million 49
Immunome Inc.: Raise no. 6, Jun 2020 × Investors in this round 49 investors had bought by the notice of Jun 16, 2020: 49 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $330,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael J Morin · Executive Officer, Director Purnanand Sarma · Executive Officer, Director I Wistar Morris · Director John R LaMattina · Director Michael D Rapoport · Director Michael D Widlitz · Director Michael R Lefenfeld · Director Philip R Wagenheim · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Purnanand Sarma, Ceo. Source: SEC Form D, newest notice filed Jun 16, 2020. Read the notice at the SEC .
equity, options SEC Nov 2019 $9 M No. 5 $2 to $10 million 35
Immunome Inc.: Raise no. 5, Nov 2019 × Investors in this round 35 investors had bought by the notice of Nov 19, 2019: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $9 M of $17 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Shares of common stock issuable upon conversion of Series A preferred stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice David D. Kutcher · Executive Officer Michael J. Morin · Executive Officer, Director Purnanand Sarma · Executive Officer, Director Scott D. Dessain · Executive Officer I. Wistar Morris · Director John R. LaMattina · Director Michael D. Rapoport · Director Michael D. Widlitz · Director Michael R. Lefenfeld · Director Philip R. Wagenheim · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Inclusive of proceeds from conversion of Notes. Series A financing expansion - to occur in multiple closings”Signed by Purnanand Sarma, Ceo. Source: SEC Form D, newest notice filed Nov 19, 2019. Read the notice at the SEC .
equity SEC Feb 2019 $7 M No. 4 $2 to $10 million 27
Immunome Inc.: Raise no. 4, Feb 2019 × Investors in this round 27 investors had bought by the notice of May 29, 2019: 27 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $315,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David D. Kutcher · Executive Officer Michael J. Morin · Executive Officer, Director Philip R. Wagenheim · Executive Officer, Director Scott D. Dessain · Executive Officer I. Wistar Morris · Director John R. LaMattina · Director Michael D. Rapoport · Director Michael D. Widlitz · Director Michael R. Lefenfeld · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Philip R. Wagenheim, Secretary. Source: SEC Form D, newest notice filed May 29, 2019. Read the notice at the SEC .
debt, options SEC May 2017 $5 M No. 3 $2 to $10 million 48
Immunome Inc.: Raise no. 3, May 2017 × Investors in this round 48 investors had bought by the notice of May 30, 2017: 48 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $315,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David D. Kutcher · Executive Officer Michael J. Morin · Executive Officer, Director Philip R. Wagenheim · Executive Officer, Director Scott D. Dessain · Executive Officer Gregory R. Harriman · Director I. Wistar Morris · Director Michael D. Rapoport · Director Michael D. Widlitz · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Kutcher, CFO and Treasurer. Source: SEC Form D, newest notice filed May 30, 2017. Read the notice at the SEC .
equity, options SEC Jul 2016 $5 M No. 2 $2 to $10 million 27
Immunome Inc.: Raise no. 2, Jul 2016 × Investors in this round 27 investors had bought by the notice of Jul 14, 2016: 27 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $12 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $756,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jane H. Hollingsworth · Executive Officer, Director Michael J. Morin · Executive Officer Gregory R. Harriman · Director I. Wistar Morris · Director Michael D. Rapoport · Director Michael D. Widlitz · Director Philip R. Wagenheim · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jane H. Hollingsworth, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 14, 2016. Read the notice at the SEC .
equity SEC Nov 2015 $4 M No. 1 $2 to $10 million 18
Immunome Inc.: Raise no. 1, Nov 2015 × Investors in this round 18 investors had bought by the notice of Dec 2, 2015: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $9 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $472,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Pennsylvania People named in the notice Jane H. Hollingsworth · Executive Officer, Director Joel Wistar Sussman · Executive Officer Gregory R. Harriman · Director I. Wistar Morris · Director Michael D. Rapoport · Director Michael D. Widlitz · Director Philip R. Wagenheim · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Broadband Capital Management LLC · New York, New York Sold in CT, FL, NC, NY, PA, WI Signed by Jane H. Hollingsworth, Executive Chair and President. Source: SEC Form D, newest notice filed Dec 2, 2015. Read the notice at the SEC .
equity, options SEC